FCB Health Network president & CEO Dana Maiman announced Jill Lesiak joined Mosaic Group – the Network’s full-service payer and market access healthcare agency – as executive creative director.

Zolgensma’s successful market uptake by payers may hold lessons for other manufacturers of costly gene therapies.

What are payers focusing on in the time of stay-at-home, work-from-home, yet still trying to serve patients? What do manufacturers need to understand? Med Ad News spoke with Greg Novello, executive VP, strategy at McCann Health Managed Markets; Adrian Garcia, senior VP, managed markets, at GSW; and Katherine Seay, executive VP, managing director, managed markets communications, Syneos Health.

Leading pharmaceutical business and marketing publication Med Ad News announces the nominees for the 31st Annual Manny Awards, honoring the best in healthcare advertising and communications. Now, more than ever, the role of effectively communicating the research, development, administration and efficacy of drug therapies to HCPs, Payers and Patients alike, is paramount to successfully navigating the world through this pandemic and beyond.

Global healthcare communications agency Fishawack Health acquired Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the United States.

Over the last few years, there has appeared to be big interest on the part of biopharma in leveraging artificial intelligence (AI) and machine learning to improve trial design and speed up drug development. Another related category is digital therapeutics (DTx), which the Digital Therapeutics Alliance says, “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage or treat a broad spectrum of physical, mental and behavioral conditions.”

Imagine a financial ecosystem that interconnects payers and providers. It’s essential to the financial well-being of any provider organization, but the current claims and payment system is inefficient and outdated. Transparency, technology and trust are 3 critical elements to evolve the payer-provider relationship for fewer denials, patient payment estimations, reduced administrative costs and more.

Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.

Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.

Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.